Global Remdesivir Market Overview
Remdesivir (GS-5734) is a nucleoside analogue prodrug. It has inhibitory effects on pathogenic animal and human coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in-vitro and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. In India, ICMR has approved remdesivir under Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 infection. Cipla has launched remdesivir under the brand name Cipremi (remdesivir lyophilised powder for injection 100 mg).
Impact of Covid-19 pandemic on market
Along with Covid-19 infections growing worldwide, governments of all Covid-19 hit nations are suffering from a shortage of essential medical supplies in order to provide optimum care to infected patients. Multiple therapeutic institutes globally are working to come up with a reliable treatment for Covid-19. One such treatment includes the use of hydroxychloroquine, while another is the use of antiviral drugs used in the disease management of HIV. Both these treatments have huge demand from advanced antivirals and antimalarial drugs. This leads the drug manufacturers as an off label indication for these drug classes has to be worked upon. The report will account for Covid19 as a key market contributor.
Global Remdesivir Market Dynamics
Demand for drugs and other related products is growing exponentially globally in order to prepare for a potential outbreak. This is a key factor projected to boost market growth to a significant extent. Major companies in the biotech industry, including research organizations such as the National Institutes of Health (NIH), US and pharmaceutical companies are being assisted by governments to develop novel vaccines and drugs to tackle this deadly virus. The key players present involved in the development of novel drugs for treating coronavirus include Cipla Limited, AbbVie Inc., Regeneron Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., and companies exploring the development of vaccines as a preventive measure include Novavax, Inc. and Inovio Pharmaceuticals, Inc. Other main factors include increasing concerns regarding outbreaks at regular intervals, rising spending on the healthcare sector, and growing need to protect the population from known and unknown viruses. Conversely, the time required for each phase of clinical trials and high cost associated with research and development of therapeutic drugs and vaccines are among some of the major factors that might limit market growth to a certain limit.
Global Remdesivir Market Segmentation
The remdesivir market is segmented based on product, application, and region.
On the basis of product, the remdesivir market is segmented into 10 Mm*1 Ml in Dmso, 5mg, 10mg, 50mg, and 100mg. On the basis of application, the global market is classified into hospital, clinics, drug store, and others.
On region, the remdesivir market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Currently, in Japan, remdesivir is approved as a treatment for patients infected with SARS-CoV-2, the virus that causes COVID-19. The U.S. Food and Drug Administration (FDA) granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. This authorization is on a temporary basis and does not take the place of the formal new drug application submission, review and approval process.
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
|
Market Segmentation |
By Product- 10 Mm*1 Ml in Dmso, 5mg, 10mg, 50mg, and 100mg By Application– Hospital, Clinics, Drug Store, and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the remdesivir market report based on product, application, and region.
Remdesivir Market, By Product:
- 10 Mm*1 Ml In Dmso
- 5mg
- 10mg
- 50mg
- 100mg
Remdesivir Market, By Application:
- Hospital
- Clinics
- Drug Store
- Others
Remdesivir Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Remdesivir Market Key Players
The key players operating in the remdesivir market includes Cipla Limited, Gilead Sciences, Kelun Pharma, Bright Gene, Hunan Warrant Pharmaceutical, and Hainan Haiyao. The key players present are involved in the development of novel drugs for treating coronavirus and are also involved in exploring the development of vaccines as a preventive measure. For instance, on June 20202, Gilead Sciences, Inc. declared topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming period.
Global Remdesivir Market Company Profile
- Gilead Sciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Cipla Limited
- Kelun Pharma
- Bright Gene
- Hunan Warrant Pharmaceutical
- Hainan Haiyao
“*” marked represents similar segmentation in other categories in the respective section
Global Remdesivir Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Remdesivir Strategies
- Key Questions this Study will Answer
- Market Snippet, By Product
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Product, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- 10 Mm*1 Ml in Dmso
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- 5mg
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- 10mg
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- 50mg
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- 100mg
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospital
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Clinics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Drug Store
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Gilead Sciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Cipla Limited
- Kelun Pharma
- Bright Gene
- Hunan Warrant Pharmaceutical
- Hainan Haiyao
- Gilead Sciences
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The remdesivir market is segmented based on product, application, and region.
Rapidly increasing confirmed cases of coronavirus disease is the major factor driving growth of the global market.
Mainly, Asia-Pacific region as In India, ICMR has approved remdesivir under Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 infection. Japan has also approved remdesivir as a treatment for patients infected with COVID-19.
As the tussle is on various pharma companies are in the development of novel drugs for the treatment of coronavirus and are also involved in exploring the vaccines solutions as a preventive measure.